Login
Congressional Trades

Congressional Trades in Alexion Pharmaceuticals, Inc.

What members of the House and Senate report owning and trading in , as filed with the House Clerk and the Senate. Every row links to the filing it came from.

Trades, last 12 months
0
by 0 members
Buys / sells
0 / 0
0 bought, 0 sold
Members reporting
0
in their latest annual report
Reported after the trade
–
median, last 12 months

Members who report holding

As filed in each member's latest annual report, in the ranges the form uses.

No sitting member's latest annual report lists .

Traded Member Trade Amount Investor Reported Source
Jul 21, 2021 Dean Phillips House · D · MN-3 Sale · Stock $1K – $15K Self Aug 13, 2021 23 days later Filing
Jul 9, 2021 James R. Langevin House · D · RI-2 Sale · Stock $15K – $50K Self Aug 14, 2021 36 days later Filing
Jan 5, 2021 Dean Phillips House · D · MN-3 Buy · Stock $1K – $15K Self Feb 13, 2021 39 days later Filing
Dec 22, 2020 Gilbert Ray Cisneros, Jr. House · D · CA-31 Partial sale · Stock $15K – $50K Self Jan 11, 2021 20 days later Filing
Dec 21, 2020 Gilbert Ray Cisneros, Jr. House · D · CA-31 Partial sale · Stock $50K – $100K Self Jan 11, 2021 21 days later Filing

Listed in annual reports

Transactions an annual report lists for the year it covers, apart from trade reports. Not counted in the trades above.

Traded Member Trade Amount Investor Report
Jan 27, 2016 John C. Carney Jr. Buy $1K – $15K Spouse 2017 Annual Report filed Feb 2, 2017
Dec 8, 2014 James R. Langevin Partial sale $1K – $15K Self 2014 Annual Report filed Aug 11, 2015
Jun 19, 2013 Lois Frankel Sale $1K – $15K Self 2013 Annual Report filed Aug 8, 2014

Members report each trade in a range, not an exact amount, and have up to 45 days to report it. Some filings are scans; where we could not read a scanned field with confidence it is left blank rather than guessed, and the filing link shows the original.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support